ALK - Five-year GRAZAX(R) Asthma Prevention (GAP) Trial Reveals Benefits of Early Treatment Intervention in Children
HORSHOLM, Denmark, July 7, 2017 * The disease modifying property of GRAZAX® (SQ® grass SLIT-tablet) resulted in long-term effect on allergic rhinoconjunctivitis (ARC) and prevented asthma symptoms, even two years after end of treatment in children with grass pollen ARC and no existing signs o...
2017-07-07 17:34
3089
ALK's ACARIZAX(R) Data Results in Significant Change to the GINA Asthma Management Strategy
HORSHOLM, Denmark, Feb. 28, 2017 /PRNewswire/ -- ALK (ALKB: DC / OMX: ALK B / AKABY / AKBLF) today announced that for the first time, allergy immunotherapy is now recommended as a treatment option in the Global Initiative for Asthma (GINA) report:Global Strategy for Asthma Management and Preventi...
2017-02-28 06:07
3229
